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Antwerp, Belgium; Auckland, New Zealand; Sao Paulo, Brazil; and Sunnyvale, CaliforniaObjectives This study sought to perform clinical and imaging assessments of the DESolve
Bioresorbable Coronary Scaffold (BCS).
Background BCS, which is drug eluting, may have potential advantages compared with conventional
metallic drug-eluting stents. The DESolve system, designed to provide vessel support and neointimal
suppression, combines a poly-L-lactic acid–based scaffold with the antiproliferative myolimus.
Methods The DESolve First-in-Man (A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION
OF THE DESolve MYOLIMUS ELUTING BIORESORBABLE CORONARY STENT IN THE TREATMENT OF
PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS) trial was a prospective multicenter
study enrolling 16 patients eligible for treatment. The principal safety endpoint was a composite of
cardiac death, myocardial infarction, and clinically indicated target lesion revascularization. The
principal imaging endpoint was in-scaffold late lumen loss (LLL) assessed by quantitative coronary
angiography (QCA) at 6 months. Intravascular ultrasound (IVUS) and optical coherence tomography
(OCT) imaging was performed at baseline and 6 months; multislice computed tomography (MSCT) was
performed at 12 months.
Results Acute procedural success was achieved in 15 of 15 patients receiving a study scaffold. At
12 months, there was no scaffold thrombosis and no major adverse cardiac events directly attributable
to the scaffold. At 6 months, in-scaffold LLL (by QCA) was 0.19  0.19 mm; neointimal volume (by IVUS)
was 7.19  3.56%, with no evidence of scaffold recoil or late malapposition. Findings were conﬁrmed
with OCT and showed uniform, thin neointimal coverage (0.12  0.04 mm). At 12 months, MSCT
demonstrated excellent vessel patency.
Conclusions This study demonstrated the feasibility and efﬁcacy of the DESolve BCS. Results showing
low in-scaffold LLL, low % neointimal volume at 6 months, no chronic recoil, and maintenance of
lumen patency at 12 months prompt further study. (DESolve First-in-Man; EudraCT number
2011-000027-32) (J Am Coll Cardiol Intv 2014;7:89–99)ª 2014 by the American College of Cardiology
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90Intracoronary stents support the vessel wall so that negative
remodeling, the major cause of restenosis after balloon
angioplasty, is prevented (1). The release of antiproliferative
drugs from drug-eluting stents (DES) help prevent the
excessive hyperplastic healing response seen after bare-metal
stent implantation. Despite their efﬁcacy (2–5), they have
not completely eliminated late events, including ongoing
inﬂammation, neoatheroma, and stent thrombosis (6,7).
Metal stents can preclude percutaneous intervention to side
branches, surgical intervention, disrupt magnetic resonance
imaging and computed tomographic imaging. Furthermore
by “caging” the artery, permanent implants prevent vaso-
motor response to physiological needs and accommodative
positive remodeling (8–10).Abbreviations
and Acronyms
%DS = percent diameter
stenosis
BCS = bioresorbable coronary
scaffold
CK = creatine kinase
DES = drug-eluting stent(s)
IVUS = intravascular
ultrasound
LLL = late lumen loss
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
MSCT = multislice computed
tomography
OCT = optical coherence
tomography
PLLA = poly-L-lactic acid
QCA = quantitative coronary
angiography
TLR = target lesion
revascularizationIn the ﬁrst clinical study using
a fully bioabsorbable, non–drug-
eluting, poly-L-lactic acid (PLLA)
stent, the Igaki-Tamai stent
(Kyoto Medical Planning Co.,
Ltd, Japan), was assessed for
feasibility and safety in 50 patients
who were followed for more than
10 years (8). The target lesion
revascularization (TLR) rate was
16%, 18%, and 28% at 1, 5, and
10 years, respectively. The major
adverse cardiac event (MACE)
rate was 14% at 12 months and
16%, 18%, 24%, and 50% at 3, 4,
5, and 10 years, respectively (8).
The high survival rate free of
cardiac death (98% at 10 years)
demonstrated the long-term
safety of the PLLA stent.
Several PLLA-based or other
polymeric bioabsorbable scaf-
folds have been clinically evalu-
ated. The term scaffold may be
a more appropriate term thanstent because it implies temporary arterial support (11).
These devices include the PLLA ABSORB BVS scaffold,
versions 1.0 and 1.1 (Abbott Vascular, Santa Clara, Cal-
ifornia), a tyrosine-derived polycarbonate polymer stent
(Reva Medical, San Diego, California), and a salicylate-
based polymer stent (Bioabsorbable Therapeutics, Menlo
Park, California) (12). Early results from the initial clinical
trials were encouraging, but issues, including too rapid
bioresorption leading to poor vessel support, scaffold
shrinkage, or strut fracture when expanded to larger diam-
eters, were seen (13). Newer iterations of these devices have
addressed some design concerns.
The DESolve Myolimus-Eluting Bioresorbable Coronary
Scaffold (BCS) System (Elixir Medical Corporation, Sun-
nyvale, California) is a PLLA-based scaffold and has severaldifferentiating characteristics. These features include: bio-
resorption at about 1 year while maintaining adequate vessel
support; the elimination of chronic recoil; the ability to
expand the scaffold without strut fracture; and unique
expansion capabilities, which minimize strut malapposition.
We report pre-clinical, bench, clinical, and imaging (quan-
titative coronary angiography [QCA], intravascular ultra-
sound [IVUS], optical coherence tomography [OCT], and
multislice computed tomography [MSCT]) results through
1 year from the DESolve First-In-Man study in 16 patients.
Methods
Study design and patient population. The DESolve First-
in-Man study was a prospective, multicenter trial enrolling
16 patients at 3 sites in Belgium and New Zealand. Eligi-
bility criteria were evidence of myocardial ischemia; a single,
de novo native coronary artery lesion; reference vessel
diameter 3.0 mm; lesion length 10 mm; and a target
lesion percent diameter stenosis (%DS) <80%. Key exclu-
sion criteria were recent (<3 days) myocardial infarction
(MI); left ventricular ejection fraction <30%; left main
coronary artery or restenotic lesions; lesions involving a side
branch >2 mm; and the presence of thrombus or calcium.
The main analysis was conducted on the per protocol–
modiﬁed intention-to-treat evaluable population inclusive of
patients who received a DESolve scaffold. One patient was
excluded because the lesion was not accessed within the
protocol-allotted procedure time and was subsequently treated
with a metallic DES. Clinical endpoints were assessed at 30
days, 6months, and1 year andwill be assessed annually through
5 years. Angiography, IVUS, and OCT assessments were
performed at baseline and at 6 months.MSCT assessment was
performed at 12 months and will be repeated at 24 months.
The ethics committee at each participating institution
approved the study protocol; all patients provided written
informed consent, which complied with the Declaration of
Helsinki. An independent clinical events committee adjudi-
cated all deaths,MI, scaffold thrombosis, and revascularizations.
Study device: DESolve scaffold platform. The DESolve
Myolimus-Eluting Bioresorbable Coronary Scaffold System
is a PLLA-based polymer scaffold coated with the anti-
proliferative drug myolimus mounted on a rapid exchange
balloon catheter delivery system.
The DESolve scaffold (Fig. 1) is formed using proprietary
techniques from a bioresorbable polylactide-based polymer
with strut thickness of 150 mm and incorporates 2 platinum-
based radio-opaque markers at either end to aid in placement.
The scaffold is coated with a matrix of polylactide-based
polymer and myolimus at a 3 mg/mm dose; more than 85% of
the drug is released over 4 weeks. The system has a crossing
proﬁle of 1.47 mm and is 6-F catheter compatible. The
scaffold is designed to resorb in about 1 year. The degradation
process of PLLA-based polymers occurs primarily by
Figure 1. The DESolve Scaffold
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91hydrolysis and is metabolized in vivo via the Krebs cycle into
carbon dioxide and water (14,15).
Important differentiating features of the DESolve scaffold
include: 1) its ability to self-correct to the vessel wall in casesFigure 2. Self-Resolution of Apposition
Intentionally created suboptimal strut apposition of a DESolve scaffold was made, aof minor malapposition when expanded to the nominal
diameter (Fig. 2), which is accomplished using a proprietary
processing technique; 2) the ability of the scaffold
to maintain radial strength and vessel support for the critical
3- to 4-month period of vessel healing (16) while subse-
quently bioresorbing in about 1 year (Figs. 3A and 3B); 3)
a wide safety margin for expansion where a 3.0-mm scaffold
can be expanded to 4.5 mm in diameter without strut
fracture (Fig. 4) (16).
In bench experiments, the self-correcting characteristic of
the DESolve scaffold was demonstrated by expanding
a DESolve scaffold inside a rigid plastic block with a rod
along the length. The rod was removed, creating an inten-
tional 0.3-mm “gap” or malapposition. After approximately
20 min, the strut malapposition was resolved (Fig. 2).
Pre-clinical in vivo test results assessing the bioresorption
proﬁle of the DESolve scaffold using molecular weight
measurements by gel permeation chromatography have
demonstrated bioresorption of the DESolve scaffold with
molecular weight reduction of >95% takes about 1 year
(Fig. 3A). In vitro degradation studies, in which the scaffold
was characterized after being placed in saline at 37C, track
closely with the in vivo data (Fig. 3B). Results show that the
scaffold maintains structural integrity and radial support to
the vessel wall for at least 3 months (17).nd progression over time until the condition self-resolved is shown.
Figure 3. DESolve Bioresorption
(A) The DESolve bioresorption proﬁle showing in vitro and in vivo bioresorption at about 1 year. Molecular weight measurements by gel permeation chromatography
were made in vivo and in vitro. (B) In vivo OCT analysis in a porcine model shows scaffold bioresorption over time, from implant to 720 days. OCT ¼ optical coherence
tomography.
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92Myolimus. Myolimus belongs to the family of macrocyclic
lactones with immunosuppressive and antiproliferative
properties.Myolimus is an analogue of rapamycin (sirolimus),
which has been used extensively to prevent organ transplant
rejection, by systemic administration. The mechanism of
action of myolimus is similar to other macrocyclic lactones
such as rapamycin, everolimus, biolimusA-9, and zotarolimus
used on DES systems and has been described elsewhere (18).Deﬁnitions. Device success was the attainment of a ﬁnal
residual %DS <50% using only a DESolve scaffold. Proce-
dural success was the attainment of a ﬁnal residual %DS of
<50% using a DESolve scaffold and any adjunct device,
without in-hospital MACE. The composite clinical
endpoint of MACE included cardiac death, target vessel
MI, and clinically indicated TLR. MI was deﬁned as the
development of new Q waves in association with a rise in
Figure 4. Scaffold Expansion Properties
Bench testing demonstrated the expansion properties and fracture resistance of the DESolve scaffold.
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93creatine kinase (CK) 2 times the upper limit of normal;
a non–Q-wave MI was deﬁned as a CK elevation 2 times
the upper limit of normal together with an elevation in
CK-myocardial band levels. Clinically indicated TLR was
met if angiographic follow-up showed a DS% 50% (QCA
assessment) with objective signs or symptoms of ischemia,Figure 5. Study Outline
IVUS ¼ intravascular; OCT ¼ optical coherence tomography; QCA ¼ quantitative coror a %DS 70% even in the absence of ischemic signs or
symptoms. Scaffold thrombosis was deﬁned according to
the protocol deﬁnition as well as the Academic Research
Consortium deﬁnition (19).
Study procedure. Standard interventional techniques were
used to treat the lesion and pre-dilation was mandatory. Theonary angiography.
Table 1. Baseline Characteristics of the Intention-to-Treat and Modiﬁed
Intention-to-Treat Patient Populations
Baseline Characteristics
Intention-to-Treat Population
(n ¼ 16)
Age, yrs 69.3 (8.4)
Male, % 10 (62.5)
History of smoking 11 (68.8)
Diabetes mellitus 1 (6.3)
Hypertension 10 (62.5)
Hypercholesterolemia 11 (68.8)
Family history of CAD 6 (37.5)
Prior myocardial infarction 4 (25.0)
Stable angina 11 (68.8)
Unstable angina 0 (0.0)
Modiﬁed Intention-to-Treat
Paired QCA Analysis
(n ¼ 14)
Target vessel
Left anterior 3 (21.4)
Left circumﬂex 5 (37.5)
Right coronary artery 6 (42.9)
AHA/ACC lesion classiﬁcation
A 5 (37.5)
B1 4 (28.6)
B2 5 (37.5)
C 0 (0.0)
Mean reference vessel diameter, mm 2.65  0.32
Minimum lumen diameter, mm 0.81  0.29
Diameter stenosis, % 69.98  10.49
Lesion length, mm 8.95  2.64
Acute gain, mm 1.54  0.36
Acute recoil, % 6.42  4.63
Values are n (%) or mean  SD.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; CAD ¼ coronary
artery disease; QCA ¼ quantitative coronary angiography.
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94DESolve scaffold was available in the 3.0  14-mm size.
Post-dilation was allowed per the physicians’ discretion. If
bailout stenting was needed, it was required that a commer-
cially available, thin-strut, “olimus”-eluting DES be used.
Loading doses of aspirin and clopidogrel were required in
patients not on chronic treatment, and procedural anti-
coagulation was according to standard hospital procedure. All
patients were to receive 75 mg of aspirin daily for the
duration of the study and clopidogrel 75mg for a minimum of
12 months per American College of Cardiology/American
Heart Association guidelines (20).
Analysis by QCA was performed by the independent
core laboratory Cardiovascular Research Center, Sao Paulo,
Brazil, using software from Medis Medical Imaging Systems,
version 7.3 (Leiden, the Netherlands). The scaffold segment
and periscaffold segments, (5 mm proximal and distal to
the edges of the scaffold) were analyzed for characteristics
including: reference vessel diameter; minimal lumendiameter; %DS for both in-scaffold and periscaffold
segments; late lumen loss (LLL); binary restenosis; and acute
recoil. Results are presented as paired matched views (post-
procedure and 6-month follow-up).
Imaging assessment using IVUS was conducted using
Boston Scientiﬁc (Natick, Massachusetts) Atlantis SR Pro
40 MHz catheters with an automated pullback speed of
0.5 mm/s. The regions at least 5 mm distal to and at least
5 mm proximal to the scaffold area were examined. Vessel,
scaffold, lumen, and intrascaffold neointimal areas, and
lumen area stenosis were calculated. Vessel, lumen, and
plaque and neointimal volumes were derived using dedicated
software. The percent neointimal obstruction was calculated
as the intrascaffold area/scaffold area  100. Incomplete
strut apposition was deﬁned as 1 or more struts separated
from the vessel wall, whereas late acquired malapposition
was a separation of 1 or more struts present at follow-up but
not present immediately post-procedure. The results are
presented as paired IVUS images (post-procedure and
6-month follow-up) and were analyzed by the Cardiovas-
cular Research Center, using the Echoplaque version
3.0.38 software (INDEC Medical Systems, Santa Clara,
California).
OCT images were acquired with a commercially available
Fourier-Domain OCT system (C7 XR, LightLab Imaging/
St. Jude Medical, Westford, Massachusetts), incorporating
a pullback system that did not require coronary artery
occlusion. Analysis of the OCT images at 0.6-mm longi-
tudinal intervals was performed with proprietary software
(LightLab Imaging). Scaffold area was delineated on the
(abluminal) side of the struts. In the absence of scaffold
malapposition and tissue prolapse, the scaffold area was
identical to the lumen area. Scaffold malapposition was
deﬁned as separation of the abluminal surface of the struts
from the luminal surface, expressed at the cross-section level
as an area, and at the strut level as the distance from the
abluminal side of each malapposed strut to the lumen.
Scaffold struts overlying a side branch were not considered
malapposed. Neointimal hyperplasia , at the cross-section
level, was calculated as (scaffold area [luminal]) minus lumen
area. At the strut-level analysis, individual struts were
assessed for the presence of tissue coverage and thickness.
The results are presented as paired OCT images (post-
procedure and 6-month follow-up) and were analyzed by the
Cardiovascular Research Center.
Multislice CT imaging was performed at 12 months after
the index procedure. All scanners were 64 detectors or
larger; images were contrast enhanced and electrocardiog-
raphy gated. The DESolve scaffold is radiolucent and
therefore not detected by MSCT aside from the radiopaque
markers at each end. The cross-sectional lumen area was
measured at 0.3-mm longitudinal intervals. The lumen
diameter was measured from the lumen area, assuming
a circular shape. In-scaffold diameter stenosis or area
Table 2. Results of Subsegmental QCA Analysis
QCA Characteristic
In-Scaffold In-Segment
Post-Procedure 180 Days p Value* Post-Procedure 180 Days p Value*
Mean reference vessel diameter, mm 2.84  0.23 2.78  0.27 0.036 2.77  0.25 2.71  0.27 0.028
Minimal lumen diameter, mm 2.60  0.19 2.41  0.28 0.0002 2.35  0.14 2.05  0.55 0.003
Diameter stenosis, % 8.05  7.90 12.63  11.37 0.049 14.64  7.06 23.84  22.05 0.267
Acute gain, mm 1.54  0.36
Acute recoil, % 6.42  4.63
Late lumen loss, mm d 0.19  0.19 0.31  0.54
Values are mean  SD. *p values are for exploratory information only and are between post-procedure and 180-day follow-up.
QCA ¼ quantitative coronary angiography.
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95stenosis was calculated as a ratio of the smallest in-scaffold
lumen diameter or area and the reference vessel diameter or
area, calculated from the interpolated proximal and distal
lumen reference. All analyses were completed at the
Cardiovascular Research Center using a Vital Images
workstation with Vitrea software, version 4.0.0.0 (Vital
Images, Minnetonka, Minnesota).
Statistical methods. This study was designed as an obser-
vational feasibility study, and thus a sample size was not
deﬁned. All clinical, angiographic, IVUS, OCT, or MSCT
endpoints were analyzed for the modiﬁed intention-to-treat
evaluable population. Categorical variables are presented as
counts (%). Paired comparisons of continuous variables
between baseline and follow-up were done by the Wilcoxon
signed rank test. For continuous variables, means, standard
deviations, and 95% conﬁdence intervals for the mean using
the Gaussian approximation were calculated. The p values
are presented as exploratory information only. Analyses were
performed using KNIME (Konstanz Information Miner,
version 2.4.2, KNIMEtech, Zurich, Switzerland) and RTable 3. Serial IVUS Measurement at Baseline and 6-Mont
IVUS Characteristics
Mo
Baseline 1
Mean scaffold area, mm2 5.35  0.78 5
Minimum scaffold area, mm2 4.46  0.65 4
Lumen area, mm2 5.34  0.78 5
Minimum lumen area, mm2 4.46  0.65 3
Plaque area, mm2 5.33  2.09 5
Lumen area stenosis, % 16.47  4.56 22
Neointimal hyperplasia area, mm2 N/A
Neointimal obstruction, % N/A 7
Malapposition 0
Values are mean  SD. *Determined by follow-up minus baseline values; y
procedure and 180-day follow-up.
CI ¼ conﬁdence interval; IVUS ¼ intravascular; N/A ¼ not available.(version 2.13.1, the R Foundation for Statistical Computing,
Vienna, Austria) statistical packages.
Results
The DESolve First-in-Man study enrolled 16 patients.
Figure 5 shows the study outline, and Table 1 shows the
patient demographics. The device was implanted success-
fully in 15 of 16 patients, and device success was demon-
strated in 14 of 16 patients. In 1 patient, the device failed to
cross the lesion in the allotted protocol-required time. In the
second case, a dissection after pre-dilation not covered by
the scaffold occurred and an overlapping metallic DES was
placed. Procedural success was achieved in 15 of 15 patients
receiving a scaffold. There was 1 hierarchical composite
endpoint of MACE through 30 days inclusive of a peri-
procedure MI following surgery to repair the treated vessel
when a dissection distal to the stented area propagated and
occluded the distal vessel, resulting in a rise in cardiac
enzymes. The patient was discharged without furtherh Follow-Up
diﬁed Intention-to-Treat Paired Analysis
(n ¼ 11)
80 Days Difference* (95% CI) p Valuey
.61  0.81 0.26 (0.06 to 0.59) 0.11
.62  0.75 0.16 (0.34 to 0.67) >0.99
.10  0.78 0.24 (0.65 to 0.16) >0.99
.92  0.57 0.54 (0.99 to 0.08) 0.23
.38  1.97 0.05 (0.53 to 0.63) 0.23
.46 (10.34) 5.99 (0.20 to 11.7) 0.23
0.4  0.2 d d
.18  3.37 d d
0 d d
p values are for exploratory information only and are between post-
Figure 6. OCT Analysis Methodology
Panel (A) demonstrates the lumen and scaffold measurements with the red
line depicting the lumen area, the blue line the luminal scaffold border, and
the green line the abluminal scaffold border; (B) the total neointimal (NI) area
including NI in between the struts; and (C) the obstructive NI area including
the NI on the luminal side of the struts. OCT ¼ optical coherence tomography.
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96sequelae. This event was adjudicated by the clinical events
committee as a non–Q-wave MI related to a target vessel
revascularization (non-target lesion) with no evidence of
scaffold thrombosis. Between 30 days and 6 months, 1 TLR
using a DES was reported for a proximal left circumﬂex
stenosis (85.9%DS) located adjacent to the widely patent
scaffold (5.9%DS). Between 6 months to 12 months, 1
event was reportedda cardiac death following non-target
vessel coronary artery bypass grafting and aortic valve
replacement. There were no cases of scaffold thrombosis as
adjudicated by the clinical events committee through the
12-month time period.Table 1 shows the patient demographics and baseline
angiographic results; Table 2 shows the post-procedure and
6-month follow-up angiographic results for the modiﬁed
intention-to-treat population. The mean in-scaffold angio-
graphic LLL was 0.19  0.19 mm, the mean in-segment
(including the proximal and distal segments) LLL was 0.3 
0.54 mm. In-scaffold binary restenosis was 0.0%, and
in-segment was 7.1% (1 of 14).
Serial IVUS demonstrated a percent neointimal obstruc-
tion result of 7.18  3.37% with an average neointimal
hyperplasia area of 0.40  0.19 mm2 (Table 3). The average
scaffold area diameter increased from 5.35  0.78 mm to
5.61  0.81 mm, whereas the lumen area was slightly
reduced from 5.35  0.78 mm2 to 5.10  0.78 mm2; neither
result was signiﬁcant. There were no cases of unresolved or
late malapposition.
The analysis of OCT imaging was performed on both the
scaffold and strut levels. Figure 6 demonstrates the analysis
procedure for measurement of the scaffold, lumen, and
neointima. There was a nonsigniﬁcant increase in scaffold
area between baseline and follow-up imaging (6.57  0.68
mm2 and 6.80  0.85 mm2, p ¼ 0.2), similar to the IVUS
results (Table 4). The struts were covered by a thin, uniform
layer of neointima in 98.7% of patients. A signiﬁcant
reduction in the number of discernible struts with preserved
box appearance was observed from baseline to follow-up
(2,987 vs. 2,575, p ¼ 0.04). A case example of the ﬁrst
patient follow-up is included in Figure 7.
Imaging using MSCT was completed at the 12-month
follow-up. The %DS was calculated to be 15.9  10%
(Table 5), demonstrating sustained luminal patency. Mean
lumen area within the scaffold was 6.7  2.5 mm2.
Discussion
The principal ﬁndings through 12 months from this
ﬁrst-in-man study demonstrated that the DESolve bio-
resorbable PLLA-based scaffold coated with a matrix of
myolimus and a biodegradable polymeric coating produced
low angiographic in-scaffold LLL (0.19 mm), similar to
that of contemporary metallic DES (4,21,22), low %
neointimal obstruction (7.18%) by IVUS at 6 months, and
few clinical events through 1 year, none of which were
directly attributable to the scaffold. OCT demonstrated
uniform coverage of neointima at 6 months, and MSCT
demonstrated good luminal patency at 1 year.
The ﬁrst absorbable scaffold implanted in humans was the
non–drug-eluting Igaki-Tamai PLLA scaffold (23). The
scaffold thickness of 170 mm was greater than newer-gene-
ration BCS, including DESolve (150 mm), and due to the
deployment sheath and the need for warmed contrast, was
cumbersome to deploy (8,23). The LLL for the Igaki-Tamai
device was >0.90 mm at 6 months, in keeping with
a non–drug-eluting device. Interestingly, there was a trend
Table 4. Serial OCT Measurement at Baseline and 6-Month Follow-Up
OCT
Modiﬁed Intention-to-Treat Paired Analysis
(n ¼ 10)
Post-Procedure 180 Days Difference* (95% CI) p Valuey
Cross-section level
Number of cross sections analyzed per scaffold 25.60  2.63 23.70  4.99 1.90 (5.03 to 1.23) 0.45
Mean scaffold area, mm2 6.57  0.68 6.80  0.85 0.23 (0.16 to 0.64) 0.34
Minimal scaffold area, mm2 5.55  0.56 5.45  0.60 0.10 (0.52 to 0.32) 0.76
Mean neointimal area, mm2 N/A 0.71  0.36 d d
Percent volume obstruction, % N/A 13.16  5.59 d d
Frequency of cross sections with malapposition, % 37/256 (14.45%) 1/237 (0.04%) d 0.01
Mean malapposition area, mm2 0.03  0.04 0.0 0.01 0.02 (0.05 to 0.001) 0.02
Strut level
Total number of struts analyzed, n 2,984 2,575 d d
Number of struts analyzed per scaffold 298.10  26.93 257.50  63.08 40.60 (86.06 to 4.86) 0.11
Number of struts analyzed per cross section 11.68  0.80 10.79  0  94 0.89 (1.50 to 0.27) 0.02
Frequency of covered struts per scaffold, % N/A 98.68 (2.44) d d
Mean neointimal thickness of covered struts, mm N/A 0.12  0.04 d d
Frequency of malapposed struts per scaffold, % 2.01  2.75 0.04  0.12 1.97 (3.95 to 0.004) 0.02
Values are mean  SD. *Determined by follow-up minus baseline values; yp values are for exploratory information only and are between post-
procedure and 180-day follow-up.
OCT ¼ optical coherence tomography; other abbreviations as in Table 3.
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97towards an increase in the in-scaffold area by IVUS between
baseline and 6 months, similar to the results of this study.
The maintenance of lumen diameter over the 10-year
follow-up period supports long-term safety of the polymeric
material (23).Figure 7. Case Example From the DESolve Study
The scaffold implanted in the mid-left anterior descending coronary artery can be s
outcome. A photograph of the MSCT shows the 2 markers of the scaffold with a widelyThe fully bioabsorbable ABSORB BVS PLLA scaffold
includes a top-coat matrix of poly-D-lactide (PDLLA) and
everolimus. The ABSORB BVS version 1.0 lost its radial
strength early and was unable to withstand the vascular
negative remodeling forces, resulting in scaffold shrinkage.een on the angiogram (between markers). OCT and IVUS show 6 months (6M)
patent lumen. CAD ¼ coronary artery disease; other abbreviations as in Figure 5.
Table 5. MSCT Analysis at 12-Month Follow-Up
MSCT In-Scaffold Analysis
12 Months
(n ¼ 12)
Reference diameter, mm 2.9  0.5
Minimal lumen diameter, mm 2.4  0.4
Mean diameter stenosis, % 15.9  10.0
Lumen area, mm2 6.7  2.5
Minimal lumen area, mm2 5.1  2.3
Values are mean  SD.
MSCT ¼ multislice computed tomography.
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98Both LLL (0.44 mm) and %DS (27%) (13) were higher
than in the current DESolve study. For the ABSORB
Cohort B (Evaluation of the Second Generation of a Bio-
resorbable Everolimus Drug-Eluting Vascular Scaffold for
Treatment of De Novo Coronary Artery Stenosis) trial,
a newer version of the device was tested (ABSORB BVS
1.1). Modiﬁcations in scaffold design and polymer pro-
cessing were made to provide prolonged vessel support;
however, resorption required 3 to 4 years (24,25). This
device was successful in limiting LLL to 0.19 mm at 6
months (26). There was, however, intolerance to post-
dilation such that strut fracture occurred when a 3.0-mm
device was dilated to >3.7 mm (14).
The acute recoil of DESolve scaffold was 6.4% and is
similar to other bioresorbable scaffolds. There was no scaf-
fold shrinkage between baseline and 6 months; rather scaf-
fold area increase was seen by both OCT (6.57 to 6.80 mm2)
and IVUS (5.35 to 5.61 mm2). Also, qualitative and quan-
titative assessment by OCT showed signiﬁcant reduction in
the number of discernible struts with preserved box
appearance between baseline and follow-up; images revealed
signs suggestive of structural discontinuity. This combina-
tion may indicate “uncaging” of the vessel and the initial
phase of scaffold degradation.
Differentiating features of the DESolve scaffold include
its ability to self-correct to the vessel wall in cases of early
malapposition, accomplished using a proprietary processing
technique, and conﬁrmed by the lack of acute malap-
position by IVUS in the paired analysis. By contrast,
ABSORB B, Cohort 1, showed 4 cases of malapposition by
IVUS at baseline (25). Additionally, the DESolve scaffold
demonstrates consistent bioresorption by about 1 year in
both in vitro and in vivo testing (16), whereas the ABSORB
scaffold (BVS 1.0) was largely resorbed by 2 years, and the
BVS 1.1 scaffold may not be complete for 3 to 4 years
(24,26,27).
Excellent vessel patency was maintained at 12 months as
demonstrated by MSCT. The in-scaffold minimal lumen
diameter of 2.40  0.40 mm was comparable to the QCA
result at 6 months (2.41  0.28 mm). Although different
imaging modalities were used, and comparisons should becarefully weighed, the mean lumen area within the scaffold
by MSCT was 6.7  2.5 mm2 at 12 months, which was
larger than that seen with IVUS at either baseline or 6
months (5.34  0.78 mm2) or 6 months (5.10  0.78 mm2).
These ﬁndings perhaps indicate some positive remodeling.
Similar observations of lumen enlargement and positive
remodeling were observed in ABSORB Cohort B, however,
at a 24-month time point (28,29), whereas the data suggest
lumen enlargement between 6 and 12 months for the
DESolve scaffold. This early change in lumen growth is an
important ﬁnding in vascular restoration therapy and may
have signiﬁcant clinical importance in the treatment of
diffuse coronary artery disease in patients with diabetes
mellitus or with acute MI, but also in the treatment of
pediatric congenital vascular abnormalities where bio-
resorbable scaffolding will not interfere with vascular growth
over time.
Myolimus was used for the ﬁrst iteration of the DESolve
scaffold. A subsequent iteration incorporating the anti-
proliferative drug, novolimus (Elixir Medical), a speciﬁcally
developed active metabolite, as well as a broad range of sizes,
are under evaluation in the DESolve Nx study.
Study limitations. Limitations include the small cohort of
patients, follow-up duration of 12 months, and lack of
randomization typical for an exploratory ﬁrst-in-man study;
however, for such a novel technology, choosing an appro-
priate control arm remains challenging.Conclusions
This ﬁrst-in-man study was designed to assess the feasibility
of the deployment of the DESolve bioresorbable scaffold in
Type A and B lesions while providing an understanding of
the device in regard to the scaffolding properties, unique
features, and the vascular response. There were few clinical
events through 12 months, none of which were directly
attributable to the coronary scaffold. Imaging data are
encouraging, and are comparable to commercially available
DES systems. At 12 months, MSCT demonstrated
the maintenance of vessel dimensions. This information
provided the necessary impetus to test the next iteration of
this novel device in a larger cohort of patients.
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